Trial Profile

Study CR9112792: A 12-month, Randomized, Double-blind, Parallel-group, Placebo and Active-controlled Dose-range Finding Study of the Efficacy and Safety of SB-751689 in Post-menopausal Women With Osteoporosis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ronacaleret (Primary) ; Alendronic acid; Teriparatide
Indications Postmenopausal osteoporosis
Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational; Therapeutic Use
Sponsors GlaxoSmithKline; GSK

08 Apr 2022 This trial has been completed in Spain (End Date: 26 Dec 2008), according to European Clinical Trials Database record.
26 Mar 2022 This trial has been completed in Belgium (End Date: 26 Dec 2008), according to European Clinical Trials Database record.
08 May 2010 Interim results were reported at the 2010 IOF World Congress on Osteoporosis and 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com